Humoral and cellular immune responses to SARS CoV-2 vaccination in People with Multiple Sclerosis and NMOSD patients receiving immunomodulatory treatments

  1. H. Bock
  2. T. Juretzek
  3. R. Handreka
  4. J. Ruhnau
  5. M. Löbel
  6. K. Reuner
  7. H. Peltroche
  8. A. Dressel

Reviewed by

Read the full article

Listed in

Log in to save this article

Abstract

No abstract available

Article activity feed

  1. Version published to 10.1016/j.msard.2022.103554
  2. ScreenIT

    SciScore for 10.1101/2021.12.22.21268127: (What is this?)

    Please note, not all rigor criteria are appropriate for all manuscripts.

    Table 1: Rigor

    EthicsIRB: of Neurology of the Carl Thiem Hospital in Cottbus was approved by the local ethics committee (Votum 2021-2124-BO-ff).
    Sex as a biological variableMedian age was 42 (range 22-70) there were 54 female and 28 male participants.
    Randomizationnot detected.
    Blindingnot detected.
    Power Analysisnot detected.

    Table 2: Resources

    Antibodies
    SentencesResources
    Neutralizing IgG antibodies: Anti-SARS-CoV-2 IgG antibodies were determined using the LIAISON® SARS-CoV-2 TrimericS IgG assay from Diasorin.
    Anti-SARS-CoV-2 IgG
    suggested: None
    The trimeric spike glycoprotein is the stabilized native form of the SARS-CoV-2 spike protein and a stabilized trimer can accurately detect the presence of neutralizing antibodies IgG.
    SARS-CoV-2 spike protein
    suggested: None
    Software and Algorithms
    SentencesResources
    Statistics: For visualization and statistical analyses Graphpad Prism 8.2 (GraphPad Software Inc.) was used.
    GraphPad
    suggested: (GraphPad Prism, RRID:SCR_002798)

    Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).

    Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:
    Another limitation of this investigation is that no data on the pre-vaccination immune-status is available and thus, previous exposure to SARS-CoV-2 may have occurred. However, apart from PwMS who were excluded for their known history of COVID disease, no other study participant showed an anti-capsid T-cell response in the T-SPOT assay, which exclusively indicates antigen contact by infection. Since, the vast majority of our patients received mRNA based vaccines, it would be of great interest to obtain similar data on PwMS who received vector based vaccines. The data presented in this study provides clear evidence on the cellular and humoral immune responses in MS and NMOSD patients receiving disease modifying therapies. With the notable exception of S1P inhibitors no treatment investigated inhibited the cellular immune response. Furthermore, the majority of patients treated with S1P inhibitors and half of the patients receiving B cell depleting therapies did show a low but detectable vaccination induced SARS-CoV-2 spike protein specific IgG production. This leaves only a small group of patients receiving S1P inhibitors for whom we could detect no immune response after vaccination. We believe that these results may aid clinicians in their decision to select the best immunomodulatory treatments for PwMS under the circumstances of the pandemic and to make informed decisions on the potential benefit of additional vaccinations.

    Results from TrialIdentifier: No clinical trial numbers were referenced.

    Results from Barzooka: We did not find any issues relating to the usage of bar graphs.

    Results from JetFighter: We did not find any issues relating to colormaps.

    Results from rtransparent:
    • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
    • No funding statement was detected.
    • No protocol registration statement was detected.

    Results from scite Reference Check: We found no unreliable references.

    About SciScore

    SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

  3. Version published to 10.1101/2021.12.22.21268127v1 on medRxiv